Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TSH BiopharmROCO:8432 +0.20%88 OCF Yield % is 14.35 as of Aug. 29, 2026, which is 391% above its 10-year median of 2.92. GuruFocus rates ROCO:8432 with a GF Score™ of 88/100 and a GF Value™ of NT$71.41 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 1,005 Drug Manufacturers companies, TSH Biopharm ranks better than 88.06% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
TSH Biopharm OCF Yield % Related Terms
TSH Biopharm OCF Yield % Historical Data
* Premium members only.
The historical data trend for TSH Biopharm's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, TSH Biopharm's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TSH Biopharm OCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TSH Biopharm's OCF Yield % distribution charts can be found below:
* The bar in red indicates where TSH Biopharm's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSH Biopharm (ROCO:8432) has a OCF Yield % of 14.35 as of Aug. 29, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on TSH Biopharm and its competitors. This is 391% above median its historical median of 2.92. According to the industry distribution chart, TSH Biopharm ranks #120 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 11.9%.
Is TSH Biopharm's OCF Yield % too high?
TSH Biopharm's current OCF Yield % of 14.35 is 391% above median its 10-year median of 2.92. The Drug Manufacturers industry median OCF Yield % is 3.41. TSH Biopharm's value of 14.35 is 320.8% above this industry median. Based on the distribution chart, TSH Biopharm ranks #120 out of 1005 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, TSH Biopharm has a GF Score™ of 88/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TSH Biopharm's OCF Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, TSH Biopharm ranks #120 out of 1005 companies for OCF Yield %. This places TSH Biopharm in the top 12% of its industry — outperforming the majority of peers. The industry median OCF Yield % is 3.41. TSH Biopharm's value of 14.35 is 320.8% above this benchmark. While the company's 10-year median is 2.92 vs. the industry median of 3.41, TSH Biopharm has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Drug Manufacturers company?
The median OCF Yield % among Drug Manufacturers companies is 3.41, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TSH Biopharm's current OCF Yield % of 14.35 is 320.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on TSH Biopharm and its competitors. For the Drug Manufacturers industry, the median OCF Yield % is 3.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TSH Biopharm's current OCF Yield % is 14.35, which is 391% above median its own 10-year median of 2.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TSH Biopharm stock overvalued right now?
Based on GuruFocus' analysis, TSH Biopharm (ROCO:8432) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$71.41, compared to a current price of NT$50.80 — trading 28.9% below its estimated fair value. The current OCF Yield % is 14.35, which is 391% above median its 10-year median of 2.92 and 320.8% above the Drug Manufacturers industry median of 3.41. TSH Biopharm's overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For TSH Biopharm (ROCO:8432), the current OCF Yield % is 14.35 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TSH Biopharm (ROCO:8432) Overvalued in 2026?
Based on GuruFocus' analysis, TSH Biopharm stock appears to be undervalued.
The current stock price of NT$50.80 is trading 28.9% below its estimated GF Value™ of NT$71.41.
GuruFocus considers TSH Biopharm to be Modestly Undervalued.
Key valuation signals for ROCO:8432:
OCF Yield %: 14.35 (391% above median its 10-year median of 2.92)
GF Value™: NT$71.41 vs. price of NT$50.80 (28.9% below fair value)
Industry Position: 320.8% above the Drug Manufacturers median (#120 of 1005)
No single metric tells the full story. See the ROCO:8432 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TSH Biopharm Corp Ltd is engaged in sale of a variety of pharmaceuticals, chemical drugs and engaged in biotechnology services. The company specializes in the development, manufacture, and marketing of branded drugs for chronic diseases. Key therapeutic areas include cardiovascular, central nervous system, gastroenterology, and severe chronic diseases, alongside precision medicine/genetic testing services .The Company's revenue is earned domestically. It earns majority of its revenue from the sale of Lozenges.
88GF Score
Get the complete analysis for ROCO:8432
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:8432 has been successfully added to your 
